62
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

, , , , , , , , , & show all
Pages 1793-1798 | Published online: 18 Sep 2014

References

  • ToniCPerugiGFrareFMataBAkiskalHSSpontaneous treatment discontinuation in panic disorder patients treated with antidepressantsActa Psychiatr Scand2004110213013715233713
  • JohnsonDADepression: treatment compliance in general practiceActa Psychiatr Scand Suppl19812904474536939323
  • PerlisRHMischoulonDSmollerJWSerotonin transporter polymorphisms and adverse effects with fluoxetine treatmentBiol Psychiatry200354987988314573314
  • PoppJLeuchtSHeresSSteimerWSerotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot studyPharmacogenomics20067215916616515395
  • MurphyGMHollanderSBRodriguesHEKremerCSchatzbergAFEffects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depressionArch Gen Psychiatry200461111163116915520364
  • HeilsATeufelAPetriSAllelic variation of human serotonin transporter gene expressionJ Neurochem1996666262126248632190
  • StahlSMEssential Psychopharmacology: Neuroscientific Basis and Practical Applications2nd edNew YorkCambridge University Press2000
  • LouieAKLewisTBLannonRAUse of low-dose fluoxetine in major depression and panic disorderJ Clin Psychiatry199354114354388270588
  • IshiguroSWatanabeTUedaMDeterminants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorderEur J Clin Pharmacol201167121213122121688171
  • BandelowBAssessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia ScaleInt Clin Psychopharmacol199510273817673659
  • Yasui-FurukoriNNakagamiTKanedaAInverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disordersHum Psychopharmacol201126860260822102561
  • MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
  • HikidaKInoueYNouchiEOhkuraYDetermination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatographyJapanese Journal of Clinical Chemistry1990194354359
  • LeschKPBengelDHeilsAAssociation of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory regionScience19962745292152715318929413
  • GartlehnerGHansenRACareyTSLohrKNGaynesBNRandolphLCDiscontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysisInt Clin Psychopharmacol2005202596915729080
  • GoetheJWWoolleySBCardoniAAWoznickiBAPiezDASelective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherenceJ Clin Psychopharmacol200727545145817873676
  • FreireRCLopesFLVerasABPersonality traits spectrum in panic disorder and major depressionRev Bras Psiquiatr2007291313417435925
  • SenSBurmeisterMGhoshDMeta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traitsAm J Med Genet B Neuropsychiatr Genet2004127B1858915108187
  • YamakawaMFukushimaASakumaKYanagisawaYKagawaYSerotonin transporter polymorphisms affect human blood glucose controlBiochem Biophys Res Commun200533441165117116038876
  • SawamuraKSuzukiYSomeyaTEffects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetineEur J Clin Pharmacol200460855355715349705
  • UedaMHirokaneGMoritaSThe impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patientsProg Neuropsychopharmacol Biol Psychiatry200630348649116423440